BNP PARIBAS ASSET MANAGEMENT Holding S.A. Increases Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 73,477 shares of the company's stock after acquiring an additional 3,382 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.09% of IDEXX Laboratories worth $37,122,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Citizens Financial Group Inc. RI boosted its holdings in IDEXX Laboratories by 26.4% in the third quarter. Citizens Financial Group Inc. RI now owns 853 shares of the company's stock worth $431,000 after purchasing an additional 178 shares during the last quarter. Moors & Cabot Inc. bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $210,000. Ontario Teachers Pension Plan Board bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $749,000. First Horizon Advisors Inc. increased its holdings in IDEXX Laboratories by 4.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 704 shares of the company's stock valued at $356,000 after acquiring an additional 27 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its stake in shares of IDEXX Laboratories by 4.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,265 shares of the company's stock worth $1,650,000 after buying an additional 131 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 0.3 %

Shares of IDXX stock traded down $1.31 during trading hours on Friday, hitting $417.24. 503,439 shares of the company were exchanged, compared to its average volume of 503,414. The company has a 50 day simple moving average of $462.53 and a two-hundred day simple moving average of $481.11. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The firm has a market cap of $34.17 billion, a P/E ratio of 40.44, a P/E/G ratio of 3.63 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.53 EPS. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. BTIG Research initiated coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They issued a "buy" rating and a $580.00 price objective for the company. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research report on Thursday, October 10th. Barclays reduced their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. JPMorgan Chase & Co. lowered their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Finally, Piper Sandler reissued a "neutral" rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of "Moderate Buy" and an average target price of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.